Skip to main content

Table 4 Clinical cure rates in clinically evaluable patients at the end of treatment.

From: Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial

  Infusion, n (%) Bolus, n (%) P- value
Overall 88/106 (83.0%) 81/108 (75.0%) 0.180
   Cured 30/106 (28.3%) 24/108 (21.3%) 0.347
   Improved 58/106 (54.7%) 57/108 (52.8%) 0.786
Culture-based therapy 86/100 (86.0%) 75/101 (74.3%) 0.051
Empiric therapy 4/6 (66.7%) 6/7 (85.7%) 0.560
Without concomitant ATB therapy potentially active against GNB 80/95 (84.2%) 76/102 (74.5%) 0.114
APACHE II > 20 37/49 (75.5%) 42/53 (79.2%) 0.813
MIC ≥ 1.5 mg/l 10/14 (71.4%) 12/21 (57.1%) 0.488
Type of infection    
   Not identified 0 1/1 (100%) 1.000
   Abdominal 15/18 (83.3%) 15/27 (55.6%) 0.063
   Respiratory 52/58 (89.7%) 47/56 (83.9%) 0.416
   Soft tissues, skin 4/5 (80.0%) 3/4 (75.0%) 1.000
   Bloodstream 7/9 (77.8%) 8/11 (72.7%) 1.000
   Urinary tract 7/11 (63.6%) 5/6 (83.3%) 0.600
   CNS 3/3 (100%) 2/2 (100%) n/a
   More sources 2/2 (100%) 1/1 (100%) n/a
  1. Values are presented as absolute (percentage). APACHE II, Acute Physiology and Chronic Health Evaluation II; ATB, antibiotic; CNS, central nervous system; GNB, Gram-negative bacteria; MIC, minimum inhibitory concentration; n/a, not applicable